Fonsatti E - Search Results

1

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Altomonte M, Fonsatti E, Visintin A, Maio M. Altomonte M, et al. Among authors: fonsatti e. Oncogene. 2003 Sep 29;22(42):6564-9. doi: 10.1038/sj.onc.1206960. Oncogene. 2003. PMID: 14528281 Review.

2

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.

Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Fonsatti E, et al. Oncogene. 2003 Sep 29;22(42):6557-63. doi: 10.1038/sj.onc.1206813. Oncogene. 2003. PMID: 14528280 Review.

3

Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma.

Altomonte M, Visintin A, Tecce R, Leonardi A, Calabro L, Fonsatti E, Pucillo C, Maio M. Altomonte M, et al. Among authors: fonsatti e. J Cell Physiol. 2004 Aug;200(2):272-6. doi: 10.1002/jcp.20015. J Cell Physiol. 2004. PMID: 15174097

4

Epigenetic immunomodulation of hematopoietic malignancies.

Gattei V, Fonsatti E, Sigalotti L, Degan M, Di Giacomo AM, Altomonte M, Calabrò L, Maio M. Gattei V, et al. Among authors: fonsatti e. Semin Oncol. 2005 Oct;32(5):503-10. doi: 10.1053/j.seminoncol.2005.07.006. Semin Oncol. 2005. PMID: 16210091 Review.

5

Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation.

Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M. Coral S, et al. Among authors: fonsatti e. Cell Growth Differ. 1997 May;8(5):581-8. Cell Growth Differ. 1997. PMID: 9149909

6

Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.

De Nardo C, Fonsatti E, Sigalotti L, Calabrò L, Colizzi F, Cortini E, Coral S, Altomonte M, Maio M. De Nardo C, et al. Among authors: fonsatti e. J Cell Physiol. 2002 Feb;190(2):200-6. doi: 10.1002/jcp.10050. J Cell Physiol. 2002. PMID: 11807824

7

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.

Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G. Maio M, et al. Among authors: fonsatti e. Cancer Immunol Immunother. 2002 Mar;51(1):9-14. doi: 10.1007/s00262-001-0249-z. Epub 2001 Dec 18. Cancer Immunol Immunother. 2002. PMID: 11845255 Free PMC article. Clinical Trial.

8

Differential levels of soluble endoglin (CD105) in myeloid malignancies.

Calabrò L, Fonsatti E, Bellomo G, Alonci A, Colizzi F, Sigalotti L, Altomonte M, Musolino C, Maio M. Calabrò L, et al. Among authors: fonsatti e. J Cell Physiol. 2003 Feb;194(2):171-5. doi: 10.1002/jcp.10200. J Cell Physiol. 2003. PMID: 12494455

9

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer.

Fonsatti E, Maio M. Fonsatti E, et al. J Transl Med. 2004 Jun 11;2(1):18. doi: 10.1186/1479-5876-2-18. J Transl Med. 2004. PMID: 15193152 Free PMC article.

10

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Fonsatti E, Di Giacomo AM, Maio M. Fonsatti E, et al. J Transl Med. 2004 Jun 25;2(1):21. doi: 10.1186/1479-5876-2-21. J Transl Med. 2004. PMID: 15219237 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters